EUVIMEDOpdag EUVIMED
Crossref

Anti‐mitotic agent SB‐216 overcomes taxane resistance in castration‐resistant prostate cancer and exhibits anti‐tumour efficacy in pancreatic cancer

Rui Wang iD, Chun Cai iD, Shanshan Deng iD, Yang Xie iD, Satyanarayana Pochampally iD, David J Hamilton iD, Bernd Meibohm iD, Evan S Glazer iD, Duane D Miller iD, Wei Li iD

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70294 ↗

At a glance

Journal article in British Journal of Pharmacology, 2025. Written by Rui Wang and 9 co-authors. Institution: Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA. Major MEDLINE topics: Prostatic Neoplasms, Castration-Resistant, Drug Resistance, Neoplasm, Pancreatic Neoplasms, Antimitotic Agents. 50 references. Funded by: NIH HHS, National Institutes of Health.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose The clinical success of small‐molecule drugs in treating pancreatic and prostate cancer patients has been both promising and challenging. Whereas patients with advanced‐stage tumours have significant initial responses to chemotherapy, many have experienced rapid resistance, metastasis and recurrence after curative‐intent surgery. Traditional tubulin inhibitors are widely used in cancer treatment, but their effectiveness is often limited by drug resistance and toxicity. SB‐216, a novel colchicine‐binding site inhibitor (CBSI), has been reported to demonstrate potential efficacy in overcoming paclitaxel (PTX) resistance in a melanoma xenograft model (A375/TxR) and inhibiting spontaneous metastasis. Experimental Approach We evaluated SB‐216 as a therapeutic option for advanced malignancies, specifically castration‐resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC). We conducted preclinical evaluations of SB‐216 in CRPC parental and taxane‐resistant lines. Additionally, we investigated the effects of SB‐216 on PDAC cells, xenograft models and patient‐derived models. Key Results In vitro, SB‐216 potently induces G2/M phase cell cycle arrest, inhibits cell proliferation, colony formation and cell migration in a concentration‐dependent manner. In vivo, SB‐216 significantly attenuates tumour growth in prostate cancer xenograft models, overcomes PTX resistance and confers a survival benefit at a dose of 2 mg kg −1 without affecting body weight. SB‐216 also inhibits the growth of PDAC xenograft tumours and the growth of patient‐derived cells and organoids. Conclusions and Implications Our findings suggest that SB‐216 is a promising candidate as a new generation of anti‐mitotic agents for advanced cancer, and further exploration in combination with other agents is warranted.

Subjects

MeSH terms (MEDLINE)

Prostatic Neoplasms, Castration-ResistantDrug Resistance, NeoplasmPancreatic NeoplasmsAntimitotic AgentsTaxoidsAntineoplastic AgentsMaleHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysMice, NudeCell ProliferationBridged-Ring CompoundsMitosis

Author keywords

castration‐resistant prostate cancercell proliferationchemotherapyorganoidspaclitaxel resistancepancreatic ductal adenocarcinomatubulin colchicine‐binding site inhibitors

Substances

Antimitotic AgentsTaxoidsAntineoplastic AgentstaxaneBridged-Ring Compounds

Authors and institutions

  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Department of Surgery, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA.
  • Department of Comparative Medicine, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA.

ORCID profiles: Rui Wang, Chun Cai, Shanshan Deng, Yang Xie, Satyanarayana Pochampally, David J Hamilton, Bernd Meibohm, Evan S Glazer, Duane D Miller, Wei Li

Funding

  • NIH HHS
  • National Institutes of Health

Cite

APA

Wang, R., Cai, C., Deng, S., Xie, Y., Pochampally, S., Hamilton, D. J., Meibohm, B., Glazer, E. S., Miller, D. D., & Li, W. (2025). Anti‐mitotic agent SB‐216 overcomes taxane resistance in castration‐resistant prostate cancer and exhibits anti‐tumour efficacy in pancreatic cancer. British Journal of Pharmacology. https://doi.org/10.1111/bph.70294

Vancouver

Wang R, Cai C, Deng S, Xie Y, Pochampally S, Hamilton DJ, et al. Anti‐mitotic agent SB‐216 overcomes taxane resistance in castration‐resistant prostate cancer and exhibits anti‐tumour efficacy in pancreatic cancer. British Journal of Pharmacology. 2025. doi:10.1111/bph.70294

BibTeX
@article{Wang2025,
  author = {Wang, Rui and Cai, Chun and Deng, Shanshan and Xie, Yang and Pochampally, Satyanarayana and Hamilton, David J and Meibohm, Bernd and Glazer, Evan S and Miller, Duane D and Li, Wei},
  title = {Anti‐mitotic agent SB‐216 overcomes taxane resistance in castration‐resistant prostate cancer and exhibits anti‐tumour efficacy in pancreatic cancer},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70294}
}
Start for free →